Evidence map›Paper›PMID 23056318›Full record

ArticlePloS one2012

Activity of the upstream component of tandem TERT/survivin promoters depends on features of the downstream component.

Irina V Alekseenko, Victor V Pleshkan, Eugene P Kopantzev, Elena A Stukacheva, Igor P Chernov, Tatyana V Vinogradova, Eugene D Sverdlov

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement.International journal of molecular sciences · 2021
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. A Universal Tumor-Specific Promoter for Cancer Gene Therapy.Doklady. Biochemistry and biophysics · 2018
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Irina V AlekseenkoInstitute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia. alekseenko.irina.v@gmail.com
Victor V Pleshkan
Eugene P Kopantzev
Elena A Stukacheva
Igor P Chernov
Tatyana V Vinogradova
Eugene D Sverdlov
Institute of Bioorganic Chemistry · RUInstitute of Molecular Genetics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We spliced the promoters of the human telomerase and human survivin genes (PhTERT and PhSurv, respectively) widely used for gene therapy and known to have the broadest cancer type spectrum of activity. Two head-to-tail constructs were obtained: the PhTERT-PhSurv and PhSurv-PhTERT tandems. The splicing caused quantitative and qualitative changes in the promoter features. In both constructs, only the promoter proximal to the transcribed gene retained its ability to initiate transcription, whereas the distal promoter was silent, the phenomenon never reported before. However, the distal promoter modulated the activity of the proximal one by increasing its strength and causing an appearance of additional transcription start sites. We suggested that this suppression might be due to the presence of Sp1 transcription factor binding sites in both promoters and Sp1-bridges between these sites. Such Sp1-bridges might convert the tandem promoter linear DNA into a stem-loop structure. If localized inside the formed loop, the distal promoter could lose its ability to initiate transcription. To test this hypothesis, we constructed two modified double promoters, where the proximal PhSurv promoter was replaced either by a shortened variant of the survivin promoter (PhSurv269) or by the mouse survivin promoter. Both PhSurv substitutes were considerably shorter than PhSurv and had different numbers and/or positions of Sp1 sites. In modified tandems, transcription was initiated from both promoters. We also prepared two mutant forms of the PhSurv-PhTERT tandem with two or four Sp1 sites removed from the distal "long" PhSurv promoter. In the first case, the distal PhSurv promoter remained silent, whereas the removal of four Sp1 binding sites restored its activity. In the majority of studied cancer cell lines the efficiency of transcription from the hTERT-(shortened hSurv269) promoter tandem was markedly higher than from each constituent promoter. In normal lung fibroblast cells, the tandem promoter activity was considerably lower.

Indexed as

Promoter Regions, GeneticAnimalsCell Line, TumorHumansInhibitor of Apoptosis ProteinsMiceMutagenesis, Site-DirectedRepressor ProteinsReverse Transcriptase Polymerase Chain ReactionSurvivinTelomeraseTranscription, GeneticBirc5 protein, mouseInhibitor of Apoptosis ProteinsRepressor ProteinsSurvivinTelomeraseTert protein, mouse

Identifiers

PMID23056318
PMCPMC3463601
OpenAlexW1968014871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.